Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Beginning Cash Balance: 2012-2024

Historic Beginning Cash Balance for Akebia Therapeutics (AKBA) over the last 13 years, with Dec 2024 value amounting to $42.9 million.

  • Akebia Therapeutics' Beginning Cash Balance rose 247.66% to $137.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.0 million, marking a year-over-year decrease of 26.89%. This contributed to the annual value of $42.9 million for FY2024, which is 53.12% down from last year.
  • According to the latest figures from FY2024, Akebia Therapeutics' Beginning Cash Balance is $42.9 million, which was down 53.12% from $91.5 million recorded in FY2023.
  • Akebia Therapeutics' Beginning Cash Balance's 5-year high stood at $229.1 million during FY2021, with a 5-year trough of $42.9 million in FY2024.
  • In the last 3 years, Akebia Therapeutics' Beginning Cash Balance had a median value of $91.5 million in 2023 and averaged $94.5 million.
  • Its Beginning Cash Balance has fluctuated over the past 5 years, first skyrocketed by 55.45% in 2021, then crashed by 53.12% in 2024.
  • Akebia Therapeutics' Beginning Cash Balance (MRY) stood at $147.4 million in 2020, then skyrocketed by 55.45% to $229.1 million in 2021, then tumbled by 34.90% to $149.1 million in 2022, then crashed by 38.64% to $91.5 million in 2023, then crashed by 53.12% to $42.9 million in 2024.
  • Its Beginning Cash Balance stands at $42.9 million for FY2024, versus $91.5 million for FY2023 and $149.1 million for FY2022.